Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VCEL by emailGet an email when VCEL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VCEL, unsubscribe in one click. Privacy
📣 What VCEL Says Is Next
in 2026 · “Remain on track to submit MACI marketing authorization application to U.K. MHRA in 2026 “The Company delivered outstanding financial and business results in the first quarter, as we generated strong revenue and profit growth and achieved several key business objectives,” said Nick Colangelo, President and CEO of Vericel.”
Company press release, May 7, 2026 · SEC filing
in 2026 · “On track to submit MACI marketing authorization application to U.K. MHRA in 2026 “The Company delivered outstanding financial and business results in the fourth quarter, as we generated strong revenue and profit growth and completed a number of key business initiatives,” said Nick Colangelo, President and CEO of Vericel.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VCEL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VCEL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.